Arcus Biosciences RCUS Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -168.6%-12.4pp | -156.3%0.0pp | -156.3%-27.2pp | -129%+180pp | -309.2%-181pp | |
| Net margin | -156.4%-13.4pp | -142.9%-0.8pp | -142.1%-28.3pp | -113.7%+164pp | -277.3%-168pp | |
| Returns | ||||||
| Return on equity | -70%-6.7pp | -63.3%+4.9pp | -68.1%-17.8pp | -50.3%+12.8pp | -63.2%-3.4pp | |
| Return on invested capital | -95.3%-25.2pp | -70.1%+32.5pp | -102.6%-27.5pp | -75.1%— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | 0.1×-0.1× | |
| Liquidity | ||||||
| Current ratio | 4×-0.3× | 4.4×+0.7× | 3.6×-0.9× | 4.5×-0.9× | 5.4×+0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×-0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.2×+0.1× | 0.1×-0.2× | |
| Per Share | ||||||
| Book value per share | $4.18-28.9% | $5.88+43.5% | $4.09-20.6% | $5.15-4.5% | $5.40+0.2% | |
| Valuation | ||||||
| Market capitalization | $2.71B-8.2% | $2.95B+104% | $1.45B+56.2% | $926.49M+11.5% | $830.86M-39.0% | |
| Price / sales | 11.5×-0.5× | 11.9×+5.9× | 6×+2.5× | 3.5×-2.4× | 5.9×+0.6× | |
| Price / book | 5.2×+0.5× | 4.7×+1.4× | 3.3×+1.6× | 1.7×+0.1× | 1.6×-1.2× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Arcus Biosciences's ratios come from?
- Every ratio is computed from Arcus Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.